Analysts expect Kalaris Therapeutics, Inc. to report revenue of 0.00 for Q3 24, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | |||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 988,467.91 | 1.46 M | 300,933.67 | |||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 890,171.85 | 1.20 M | 264,018.03 | |||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 939,319.88 | 1.33 M | 282,475.85 |
Analysts expect Kalaris Therapeutics, Inc. to report earnings per share of -2.26 for Q3 24, against a range of -2.43 to -2.09. The most recent reported quarter, Q2 26, came in at -0.48, a 4.3% miss against the -0.46 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | -3.29 | -2.52 | -0.61 | -0.64 | -0.47 | -0.46 | -0.48 | - | - | - | - | - | - | - | |||||||||||
| High Estimate | -2.09 | -2.37 | -0.70 | -0.45 | -0.54 | -0.56 | -0.47 | -0.42 | -0.47 | -0.49 | -0.49 | -0.40 | -0.28 | -0.24 | -0.60 | |||||||||||
| Low Estimate | -2.43 | -2.79 | -0.78 | -0.53 | -0.60 | -0.66 | -0.55 | -0.50 | -0.55 | -0.55 | -0.53 | -0.44 | -0.34 | -0.28 | -0.72 | |||||||||||
| Consensus Estimate | -2.26 | -2.58 | -0.74 | -0.49 | -0.57 | -0.61 | -0.51 | -0.46 | -0.51 | -0.52 | -0.51 | -0.42 | -0.31 | -0.26 | -0.66 |
Pull Wall Street consensus for Kalaris Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=KLRS&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "KLRS", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=KLRS&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();